These medications remain expensive, costing more than $16,000 per patient per year for some patients, and employers, health plans, and patients are feeling it
Comparisons With Other Diabetes Therapies Putting GLP1s in context with other antidiabetic agents offers additional insights: Thiazolidinediones (TZDs) are associated with increased fracture risk, especially in women SGLT2 inhibitors have raised concerns in some trials, particularly canagliflozin DPP-4 inhibitors appear largely neutral regarding skeletal effects Against this backdrop, GLP1s may have a neutral or possibly safer profile, though the data are not conclusive
Louwagie, MD, PhD, Department of Internal Medicine, LewisGale Hospital Montgomery, Blacksburg, Va
Standard water-based solutions may struggle to penetrate the scalps lipid barrier effectively
References CountingStars
Long-term effects unknown